bluebird bio Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
54.16 M |
Public Float |
31.37 M |
bluebird bio Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$11.36 |
Market Cap |
$7.05 B |
Shares Outstanding |
55.12 M |
Public Float |
54.5 M |
Address |
60 Binney Street Cambridge Massachusetts 02142 United States |
Employees | - |
Website | http://www.bluebirdbio.com |
Updated | 07/08/2019 |
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy. |